Literature DB >> 15704139

Prostaglandin E and prostacyclin receptor expression in tumor and host tissues from MCG 101-bearing mice: a model with prostanoid-related cachexia.

Wenhua Wang1, Marianne Andersson, Christina Lõnnroth, Elisabeth Svanberg, Kent Lundholm.   

Abstract

Preclinical and clinical studies in our laboratory have suggested that prostaglandin (PG) E2 is involved in anorexia and cachexia development, although the role of COX pathways on the pathogenesis of cancer cachexia remains to be clarified. Expressions of PGE (EP1, EP2, EP3alpha,beta,gamma and EP4) and PGI (IP) receptors in the central nervous system (brain cortex, hypothalamus and brain stem), in peripheral (liver, white adipose tissue and skeletal muscle) and tumor tissue from MCG-101-bearing mice with and without indomethacin treatment were investigated by RT-PCR and immunohistochemistry. Expression of EP1 in the liver and EP4 receptor in white adipose tissue were upregulated and responded to indomethacin treatment, while downregulated expression of EP3 in skeletal muscle from tumor-bearing mice was unresponsive to indomethacin treatment despite improved carcass weight. Expression of EP and IP receptors in brain and tumor tissue from tumor-bearing mice were neither related nor responsive to systemic PGE2 levels including increased IL-1beta, IL-6 and TNF-alpha host activities. The expression IP receptor in CNS, peripheral tissue and tumor tissue was unchanged by cachexia development. Our results suggest that transcription of EP receptors in liver, fat and skeletal muscle tissue may be a control level for host metabolic alterations during tumor progression, while overall EP and IP receptor expression in CNS did not indicate an important control level for appetite regulation in MCG 101-bearing mice despite prostanoid related anorexia. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15704139     DOI: 10.1002/ijc.20539

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

Review 1.  Mechanotransduction in skeletal muscle.

Authors:  Thomas J Burkholder
Journal:  Front Biosci       Date:  2007-01-01

Review 2.  The burning furnace: Alteration in lipid metabolism in cancer-associated cachexia.

Authors:  Mit Joshi; Bhoomika M Patel
Journal:  Mol Cell Biochem       Date:  2022-03-07       Impact factor: 3.396

3.  Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia.

Authors:  Giovanni Mantovani; Antonio Macciò; Clelia Madeddu; Roberto Serpe; Giorgia Antoni; Elena Massa; Mariele Dessì; Filomena Panzone
Journal:  J Mol Med (Berl)       Date:  2009-10-03       Impact factor: 4.599

4.  Food intake, tumor growth, and weight loss in EP2 receptor subtype knockout mice bearing PGE2-producing tumors.

Authors:  Britt-Marie Iresjö; Wenhua Wang; Camilla Nilsberth; Marianne Andersson; Christina Lönnroth; Ulrika Smedh
Journal:  Physiol Rep       Date:  2015-07

5.  Role of Cyclooxygenase-2 on Intermittent Hypoxia-Induced Lung Tumor Malignancy in a Mouse Model of Sleep Apnea.

Authors:  Noelia Campillo; Marta Torres; Antoni Vilaseca; Paula Naomi Nonaka; David Gozal; Jordi Roca-Ferrer; César Picado; Josep Maria Montserrat; Ramon Farré; Daniel Navajas; Isaac Almendros
Journal:  Sci Rep       Date:  2017-03-16       Impact factor: 4.379

6.  Inflammation-induced cholestasis in cancer cachexia.

Authors:  Morgane M Thibaut; Martina Sboarina; Martin Roumain; Sarah A Pötgens; Audrey M Neyrinck; Florence Destrée; Justine Gillard; Isabelle A Leclercq; Guillaume Dachy; Jean-Baptiste Demoulin; Anne Tailleux; Sophie Lestavel; Marialetizia Rastelli; Amandine Everard; Patrice D Cani; Paolo E Porporato; Audrey Loumaye; Jean-Paul Thissen; Giulio G Muccioli; Nathalie M Delzenne; Laure B Bindels
Journal:  J Cachexia Sarcopenia Muscle       Date:  2020-12-22       Impact factor: 12.910

7.  LPS immune challenge reduces arcuate nucleus TSHR and CART mRNA and elevates plasma CART peptides.

Authors:  Jonathan R Burgos; Britt-Marie Iresjö; Linda Olsson; Ulrika Smedh
Journal:  BMC Neurosci       Date:  2019-12-11       Impact factor: 3.288

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.